688062 邁威生物
按盤價 
23.850 -1.410 (-5.582%) | 2025/03 - 三個月 人民幣(K¥) | 與去年同期 比較 | 2024/12 人民幣(K¥) | 2023/12 人民幣(K¥) | 2022/12 人民幣(K¥) | 2021/12 人民幣(K¥) | ||
| 營業總收入 | 44,788 | -33.70% | 199,782 | 127,836 | 27,728 | 16,226 | |
| 減：營業總成本 | 336,095 | 18.91% | 1,259,798 | 1,175,895 | 993,419 | 819,034 | |
| 其中:營業成本 | 9,976 | 1,027.86% | 28,952 | 1,370 | 71 | 3,079 | |
| 財務費用 | 17,287 | 343.82% | 36,726 | (33,411) | (34,764) | 3,478 | |
| 資產減值損失 | (2,718) | -0.83% | (5,527) | (9,488) | (1,940) | (2,144) | |
| 公允價值變動收益 | 18 | -78.16% | 493 | (3,043) | 1,082 | (230) | |
| 投資收益 | (1,459) | -685.57% | (4,219) | (1,649) | 714 | 4,084 | |
| 其中：對聯營企業和合營企業的投資收益 | (1,726) | 209.47% | (7,058) | (2,594) | (476) | (176) | |
| 營業利潤 | (291,021) | 41.13% | (1,043,480) | (1,052,579) | (958,139) | (772,696) | |
| 利潤總額 | (292,403) | 41.80% | (1,047,471) | (1,055,288) | (958,126) | (772,700) | |
| 減：所得稅費用 | 54 | -- | (907) | 3,524 | -- | -- | |
| 淨利潤 | (292,458) | 41.82% | (1,046,565) | (1,058,811) | (958,126) | (772,700) | |
| 減：非控股權益 | (730) | 32.12% | (2,645) | (5,379) | (2,891) | (3,113) | |
| 股東淨利潤 | (291,728) | 41.85% | (1,043,919) | (1,053,433) | (955,235) | (769,587) | |
市場價值指標 | |||||||
| 每股收益 (元) * | -0.730 | 43.14% | -2.610 | -2.640 | -2.440 | -2.570 | |
| 每股派息 (元) * | -- | -- | -- | -- | -- | -- | |
| 每股淨資產 (元) * | 3.196 | -46.93% | 3.926 | 6.466 | 8.798 | 3.373 | |
| 審計意見 # | -- | 标准无保留意见 | 标准无保留意见 | 标准无保留意见 | 标准无保留意见 | ||
| 備註： | *未調整數據 |
| #只提供簡體內容 | |
| 即時報價更新時間為 26/06/2025 16:30 |
- 經濟通
- 強化版MQ
- 強化版TQ
- 財曆
- Mobile
Web
